Elevated circulating levels of interleukin-6 in patients with chronic renal failure.

@article{Herbelin1991ElevatedCL,
  title={Elevated circulating levels of interleukin-6 in patients with chronic renal failure.},
  author={Andr{\'e} Herbelin and Pablo Ure{\~n}a and Anh Thu Nguyen and Johanna Zingraff and Béatrice Descamps-Latscha},
  journal={Kidney international},
  year={1991},
  volume={39 5},
  pages={
          954-60
        }
}
In a previous study, we demonstrated the presence of circulating interleukin-1 (IL-1) in long-term dialyzed patients and that of tumor necrosis factor alpha (TNF alpha) in both long-term and not yet dialyzed uremic patients. In the present study, we attempted to determine the respective influence of hemodialysis (HD) and uremia on the plasma level of interleukin-6 (IL-6), which shares several biological properties with IL-1 and TNF alpha, including the induction of the acute phase response of… 

Serum Concentration of IL-2, IL-6, TNF-Alpha and Their Soluble Receptors in Children on Maintenance Hemodialysis

The data suggest that immune cells in HD children are in an activated state and that neither a single dialysis session nor the type of dialyzer membrane has an influence on the cytokines examined.

Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients

The presence of naturally occurring inhibitors of interleukin-1 (IL-1) and tumor necrosis factor (TNF) in a variety of diseases has been demonstrated. The IL-1 receptor antagonist (IL-1Ra) binds to

Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells.

The role of this cytokine in the inflammatory response induced by blood interaction with hemodialysis membranes is evaluated and the relationship between IL-6 synthesis and release and beta-2-microglobulin (beta 2m) production is evaluated.

Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients.

There is a correlation between an overproduction of interleukin-(IL)-6 and tumor necrosis factor alpha upon stimulation with LPS by mononuclear cells in vitro and the clinical grade of immunodeficiency found in patients with chronic renal failure and hemodialysis treatment.

Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation.

In peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD), CAPD induces per se PBMC activation with an enhanced release of both IL-6 and beta 2m; this is associated to higher levels of SAA.

Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin.

It is concluded that proinflammatory cytokines are elevated in pediatric HD and PD patients without counterbalance from anti- inflammatory cytokines, and aspirin therapy attenuates inflammation.

Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.

  • R. BologaD. M. Levine A. Rubin
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1998
The data support the view that hypoalbuminemia and hypocholesterolemia are negative acute-phase responses to inflammatory stimuli and suggest that efforts to identify the nature of the stimuli for cytokine production and to lower cytokine levels in hemodialysis patients might be effective in improving the survival of patients undergoing he modialysis.

Effect of hepatitis C virus on C-reactive protein and interleukin-6 in hemodialysis patients.

High serum IL-6 and CRP levels are found in HCV-positive hemodialysis patients, compared withHCV-negative ones, however, it is failed to show the significance of these differences.

Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.

Plasma IL-6 significantly predicted overall and cardiovascular mortality; this association persisted after multiple adjustments or restricting the analysis to pre-dialysis patients, and was a significantly better predictor of mortality than C-reactive protein, albumin or tumor necrosis factor-alpha.

Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease.

...

References

SHOWING 1-10 OF 42 REFERENCES

Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha.

The concomitant presence of IL-1 and TNF alpha in the plasma of long-term HD patients could be responsible for some of the clinical features observed in these patients, and provides strong evidence favoring the concept that HD can be assimilated to a recurrent acute-phase inflammatory response.

Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes.

The consequences of monocyte hemodialysis stimulation may be obtained locally, even in the presence of unchanged or reduced plasma IL-1 activity, by the presence or absence of the membrane's ability to remove and/or absorbIL-1.

Blood-membrane interaction in hemodialysis leads to increased cytokine production.

Recently much interest has been focused on the role of immunoregulatory cytokines such as interleukin 1 (IL 1) and interleukin 2 (IL 2) during the pathogenesis of immunological as well as

Endotoxemia in chronic renal failure.

Differences in endotoxin levels in patients on peritoneal or hemodialysis treatment may reflect that extracorporeal circulation enhances endotoxin entrance to the circulation and/or that endotoxin clearance is dependent on the dialysis regimen.

In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients.

A similar pattern of T cell abnormalities was observed in the uremic non-hemodialyzed patients studied, and a significantly decreased IL-2 activity was detected in the supernatants of stimulated T cells from hemodialyzing patients.

IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.

It is concluded that rTNF administration in man leads to the induction of circulating IL-6 which, due to its broad range of activities, may be an important physiologic signal regulating the immune response.

Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

IFN-beta 2/IL-6 is likely one of the endogenous mediators which is triggered in man during bacterial infection and likely participates in the metabolic and immune responses of the infected host.

The serum interleukin 6 response to elective surgery.

Serum IL-6 is an early marker of tissue damage and may be of value in the study of the metabolic response to injury and the length of the operation in patients undergoing elective cholecystectomy.

Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes.

The hypothesis that hemodialysis with regenerated cellulose might augment IL-1 production in endstage renal disease patients maintained on longterm hemodIALysis is supported and it is demonstrated for the first time that dialysis patients have detectable plasma levels of interleukin-1 compared to normal individuals.

Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

A specific radioimmunoassay was developed and used for IL-6 to compare production of this cytokine on a molar basis with that of IL-1 alpha,IL-1 beta, and tumor necrosis factor (TNF)alpha, and there was a significant correlation betweenIL-6 and IL-2 beta (r = .72) and between IL-4 and TNF ( r = .66).